A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P)

Related Experiment Videos

Dietmar W Siemann1, David J Chaplin, Patricia A Walicke

  • 1Department of Radiation Oncology, University of Florida, 2000 SW Archer Road, Gainesville, FL 32610, USA. siemadw@ufl.edu

Expert Opinion on Investigational Drugs
|February 25, 2009
PubMed

Insights

Vascular-disrupting agents (VDAs) like combretastatin-A4 phosphate (CA4P) shut down tumor blood vessels, causing cancer cell death. Combining VDAs with other therapies shows promise for improved cancer treatment outcomes.

Area of Science:

  • Oncology
  • Vascular Biology
  • Pharmacology

Background:

  • Tumor progression and metastasis rely on a robust blood vessel network.
  • Vascular-disrupting agents (VDAs) target and shut down tumor vasculature.
  • Combretastatin-A4 phosphate (CA4P) is a key tubulin depolymerizing agent in this strategy.

Purpose of the Study:

  • To review the efficacy of vascular-disrupting agents (VDAs) in cancer therapy.
  • To highlight the potential of combretastatin-A4 phosphate (CA4P) as a lead VDA.
  • To explore combination strategies involving VDAs.

Main Methods:

  • Review of preclinical and clinical data on VDAs, focusing on CA4P.
  • Analysis of CA4P's effects on tumor vascular networks and cell death.
  • Evaluation of combination therapies including chemotherapy, radiotherapy, and antiangiogenic agents.

Main Results:

  • CA4P monotherapy induces significant tumor necrosis and reduces blood flow in preclinical models and patient tumors.
  • CA4P demonstrates synergistic effects when combined with chemotherapy and radiotherapy.
  • Preclinical data suggest VDAs combined with antiangiogenic therapies are promising.

Conclusions:

  • VDAs, particularly CA4P, are effective in targeting tumor vasculature.
  • Combination therapies involving VDAs offer enhanced therapeutic potential for cancer treatment.
  • Further clinical evaluation of VDA combinations is warranted.

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Peripheral Artery Disease IV: Nursing Management01:26

Peripheral Artery Disease IV: Nursing Management

The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses, temperature changes,...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...